Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting
- 19 May 2022
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (20) , 2533-2543
Abstract
Aims: To determine the antiemetic efficacy of a 6-day aprepitant schedule in patients receiving multiple-day cisplatin. Patients & methods: Patients diagnosed with lung cancer and who were chemothe... Plain language summary The aim of this study was to determine the effectiveness of a 6-day aprepitant schedule in patients receiving a multiple-day highly emetogenic chemotherapy drug (cisplatin). ...Keywords
This publication has 17 references indexed in Scilit:
- Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic reviewCritical Reviews in Oncology/Hematology, 2016
- Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapyBioMed Research International, 2015
- Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and SafetyThe Oncologist, 2015
- Optimizing lung cancer treatment approachesNature Reviews Clinical Oncology, 2014
- Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapySupportive Care in Cancer, 2014
- Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy‐induced nausea and vomiting in patients receiving multiple‐day cisplatin chemotherapyInternal Medicine Journal, 2013
- Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapySupportive Care in Cancer, 2012
- Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group StudyJournal of Clinical Oncology, 2012
- Aprepitant: drug–drug interactions in perspectiveAnnals of Oncology, 2010
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003